112 related articles for article (PubMed ID: 24482497)
1. Inhibitory FcγRIIb and CD20 internalization.
Dransfield I
Blood; 2014 Jan; 123(5):606-7. PubMed ID: 24482497
[TBL] [Abstract][Full Text] [Related]
2. Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.
Vaughan AT; Chan CH; Klein C; Glennie MJ; Beers SA; Cragg MS
J Biol Chem; 2015 Feb; 290(9):5424-37. PubMed ID: 25568316
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.
Vaughan AT; Iriyama C; Beers SA; Chan CH; Lim SH; Williams EL; Shah V; Roghanian A; Frendéus B; Glennie MJ; Cragg MS
Blood; 2014 Jan; 123(5):669-77. PubMed ID: 24227819
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Clynes RA; Towers TL; Presta LG; Ravetch JV
Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
[TBL] [Abstract][Full Text] [Related]
6. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
7. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
8. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Williams EL; Tutt AL; French RR; Chan HT; Lau B; Penfold CA; Mockridge CI; Roghanian A; Cox KL; Verbeek JS; Glennie MJ; Cragg MS
Eur J Immunol; 2012 Aug; 42(8):2109-20. PubMed ID: 22760702
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SM201, an anti-hFcγRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells.
Rieth N; Carle A; Müller MA; ter Meer D; Direnberger C; Pohl T; Sondermann P
Immunol Lett; 2014 Aug; 160(2):145-50. PubMed ID: 24472604
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
11. Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Roghanian A; Teige I; Mårtensson L; Cox KL; Kovacek M; Ljungars A; Mattson J; Sundberg A; Vaughan AT; Shah V; Smyth NR; Sheth B; Chan HT; Li ZC; Williams EL; Manfredi G; Oldham RJ; Mockridge CI; James SA; Dahal LN; Hussain K; Nilsson B; Verbeek JS; Juliusson G; Hansson M; Jerkeman M; Johnson PW; Davies A; Beers SA; Glennie MJ; Frendéus B; Cragg MS
Cancer Cell; 2015 Apr; 27(4):473-88. PubMed ID: 25873171
[TBL] [Abstract][Full Text] [Related]
12. FcγRIIB as a key determinant of agonistic antibody efficacy.
White AL; Beers SA; Cragg MS
Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
[TBL] [Abstract][Full Text] [Related]
13. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
14. B lymphocytes undergo apoptosis because of FcgammaRIIb stress response to infection: a novel mechanism of cell death in sepsis.
Pinheiro-da-Silva F; Chiamolera M; Charles N; Kanamaru Y; Velasco IT; Benhamou M; Monteiro RC
Shock; 2006 Jan; 25(1):61-5. PubMed ID: 16369188
[TBL] [Abstract][Full Text] [Related]
15. Lower antibody response to Porphyromonas gingivalis associated with immunoglobulin G Fcgamma receptor IIB polymorphism.
Honma Y; Sugita N; Kobayashi T; Abiko Y; Yoshie H
J Periodontal Res; 2008 Dec; 43(6):706-11. PubMed ID: 18705654
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.
Stopforth RJ; Cleary KL; Cragg MS
J Clin Immunol; 2016 May; 36 Suppl 1():88-94. PubMed ID: 26922075
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.
Chu SY; Vostiar I; Karki S; Moore GL; Lazar GA; Pong E; Joyce PF; Szymkowski DE; Desjarlais JR
Mol Immunol; 2008 Sep; 45(15):3926-33. PubMed ID: 18691763
[TBL] [Abstract][Full Text] [Related]
18. Releasing the brakes: targeting FcγRIIB on B cells to enhance antibody-dependent lymphoma immunotherapy.
Seeling M; Nimmerjahn F
Cancer Cell; 2015 Apr; 27(4):427-8. PubMed ID: 25873165
[TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
Hamaguchi Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):29-34. PubMed ID: 19252375
[TBL] [Abstract][Full Text] [Related]
20. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
